Asset Details
Do you wish to reserve the book?
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Do you wish to request the book?
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
2017
Overview
In a randomized trial, children with uveitis associated with juvenile idiopathic arthritis who were taking a stable dose of methotrexate were significantly less likely to have treatment failure but more likely to have adverse events with adalimumab than with placebo.
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk for inflammation of the uvea (uveitis). Uveitis develops in approximately 12 to 38% of patients with JIA within 7 years after the onset of arthritis.
1
,
2
Despite current screening and therapeutic options, visual impairment in both eyes may develop in up to 15% of children with JIA-associated uveitis, and they may be certified as legally blind.
3
,
4
Experimental models of autoimmune uveitis have shown that tumor necrosis factor α (TNF-α) plays a pivotal role in the pathogenesis,
5
findings that have been borne . . .
Publisher
Massachusetts Medical Society
Subject
/ Adalimumab - therapeutic use
/ Anti-Inflammatory Agents - adverse effects
/ Anti-Inflammatory Agents - therapeutic use
/ Antirheumatic Agents - therapeutic use
/ Arthritis, Juvenile - complications
/ Arthritis, Juvenile - drug therapy
/ Child
/ Children
/ Female
/ Humans
/ Male
/ Methotrexate - therapeutic use
/ Patients
/ Uveitis
